ArticleJournal of neuro-oncology2023

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.

Johannes Weller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.